Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID-19 severe or critically meta-analysis

REMAP-CAP tocilizumab, 2021
 
NCT02735707
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
353/402 conclusif -27% demonstrated58%
Veiga, 2021
 
NCT04403685
RCTtocilizumab controlCOVID-19 severe or criticallysome concern
65/64 safety concern safety concern149% 49%
BACC Bay Tocilizumab Trial, 2020
 
NCT04356937
RCTtocilizumab placeboCOVID-19 severe or criticallylow
161/81 inconclusive 47% 5% -15%
COVACTA (Rosas), 2020
 
NCT04320615
RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
294/144 inconclusive 2% 17%
Andrew, 2020 OBStocilizumab controlCOVID-19 severe or criticallyNA
198/413 inconclusive -22%
Biran, 2020 OBStocilizumab controlCOVID-19 severe or criticallyserious
210/420 suggested -32%
Mathilde, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
30/29 suggested -68%
Rojas-Marte, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
96/97 inconclusive -34%
Somers, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
78/76 safety concern -40%
TOCI-RAF Study Group (Campochiaro), 2020 OBStocilizumab controlCOVID-19 severe or criticallyNA
32/33 inconclusive -57%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).